1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow oNKord®: new trials by email Literature Review of oNKord® trials Research Report on oNKord®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Registry of Patients Having Received oNKord® oNKord®, Cyclophosphamide/Fludarabine (Cy/Flu) - AML | Recruiting | Glycostem Therapeutics BV | 50 | 2022-06-14 | 2022-08-04 | |
| A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia Cyclophosphamide-Fludarabine (Cy/Flu), oNKord® - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Glycostem Therapeutics BV | 33 | 2020-12-08 | 2022-06-21 |
Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1)
Germany (2) · Switzerland (2) · Belgium (1) · France (1) · Netherlands (1)
Prof. Dr. Arnold Ganser, MD (1)
2019 (1)